SYNLAB AG |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 10.48 EUR | +0.77% |
|
+1.16% | -8.23% |
| May. 08 | Transcript : SYNLAB AG, Q1 2024 Earnings Call, May 08, 2024 | |
| May. 08 | Laboratory chain Synlab starts the year with lower revenue | DP |
| Sales 2024 * | 2.86B 3.09B | Sales 2025 * | 3.02B 3.27B | Capitalization | 2.3B 2.49B |
|---|---|---|---|---|---|
| Net income 2024 * | 81M 87.58M | Net income 2025 * | 67M 72.45M | EV / Sales 2024 * | 1.32 x |
| Net Debt 2024 * | 1.47B 1.59B | Net Debt 2025 * | 1.64B 1.77B | EV / Sales 2025 * | 1.3 x |
| P/E ratio 2024 * |
28.3
x | P/E ratio 2025 * |
34.9
x | Employees | 27,000 |
| Yield 2024 * |
1.96% | Yield 2025 * |
1.96% | Free-Float | 14.22% |
More Fundamentals
* Assessed data
More news
Latest transcript on SYNLAB AG
More press releases
| 1 day | +0.77% | ||
| 1 week | +1.16% | ||
| Current month | -0.19% | ||
| 1 month | -0.76% | ||
| 3 months | -10.73% | ||
| 6 months | -3.32% | ||
| Current year | -8.23% |
1 week
10.20
10.48
1 month
10.2010.64
Current year
10.1012.43
1 year
8.0212.43
3 years
6.6825.00
5 years
6.6825.00
10 years
6.6825.00
| Managers | Title | Age | Since |
|---|---|---|---|
Mathieu Floreani
CEO | Chief Executive Officer | 56 | 21-01-25 |
Sami Badarani
DFI | Director of Finance/CFO | 61 | 21-01-25 |
Henrik Andreasen
CTO | Chief Tech/Sci/R&D Officer | - | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
David Ebsworth
CHM | Chairman | 69 | 21-01-10 |
| Founder | 63 | 97-12-31 | |
Marc Welters
BRD | Director/Board Member | - | 21-04-28 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 1.29% | 125 M€ | -.--% | ||
| 0.55% | 17 M€ | -.--% | - | |
| 0.18% | 18 M€ | +7.68% |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-23 | 10.48 | +0.77% | 7,573 |
| 24-05-22 | 10.4 | +0.78% | 5,601 |
| 24-05-21 | 10.32 | 0.00% | 13,745 |
| 24-05-20 | 10.32 | +1.18% | 2,957 |
| 24-05-17 | 10.2 | -1.35% | 31,167 |
Delayed Quote Xetra, May 23, 2024 at 11:35 am EDT
More quotes
Synlab AG is a Germany based clinical laboratory and medical diagnostic services provider. The Company is engaged in laboratory services for human and veterinary medicine, as well as environmental analysis.
Calendar
2024-08-07
- Q2 2024 Earnings Call
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
2
Last Close Price
10.48
EUR
Average target price
14.5
EUR
Spread / Average Target
+38.36%
EPS Revisions
Quarterly revenue - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -8.23% | 2.48B | |
| -20.70% | 7.83B | |
| +0.14% | 2.58B | |
| -40.47% | 2.46B | |
| -14.15% | 1.84B | |
| -20.84% | 1.53B | |
| -42.17% | 1.22B | |
| +16.01% | 1.2B | |
| +14.92% | 961M | |
| -15.23% | 920M |
- Stock Market
- Equities
- SYAB Stock
